IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment

IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, with varied clinical and histopathological features between individuals, particularly across races. As an autoimmune disease, IgAN arises from consequences of increased circulating levels of galactose-defici...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostics (Basel) Vol. 13; no. 2; p. 303
Main Authors: Du, Yating, Cheng, Tingzhu, Liu, Chenxuan, Zhu, Tingting, Guo, Chuan, Li, Shen, Rao, Xiangrong, Li, Jinpu
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 13-01-2023
MDPI
Subjects:
Antigens
Asymptomatic
Autoimmune diseases
Biopsy
complement dysregulation
Cytokines
Gd-IgA1
Hypotheses
immunoglobulin A nephropathy
Immunology
Infections
Ligands
microbiota
mucosa-associated lymphoid tissue
mucosal immunity
Pathogenesis
Review
Throat surgery
Asia
microbiota
complement dysregulation
immunoglobulin A nephropathy
Gd-IgA1
clinical trials
mucosa-associated lymphoid tissue
translational researches
prognosis
mucosal immunity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, with varied clinical and histopathological features between individuals, particularly across races. As an autoimmune disease, IgAN arises from consequences of increased circulating levels of galactose-deficient IgA1 and mesangial deposition of IgA-containing immune complexes, which are recognized as key events in the widely accepted "multi-hit" pathogenesis of IgAN. The emerging evidence further provides insights into the role of genes, environment, mucosal immunity and complement system. These developments are paralleled by the increasing availability of diagnostic tools, potential biomarkers and therapeutic agents. In this review, we summarize current evidence and outline novel findings in the prognosis, clinical trials and translational research from the updated perspectives of IgAN pathogenesis.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors contributed equally to this work.
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics13020303